Advertisement Pharmaceutical Business review - Page 362 of 5222 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
September 30, 2024

AbbVie seeks FDA approval for non-small cell lung cancer treatment

AbbVie has filed a biologics license application (BLA) with the US Food and Drug Administration (FDA) seeking accelerated approval for telisotuzumab vedotin (Teliso-V) in adult non-small cell lung cancer (NSCLC) patients.

Continue
The company filed a BLA seeking accelerated approval for Teliso-V, targeting non-small cell lung cancer with c-Met overexpression. Credit: © AbbVie Inc. All rights reserved.
September 27, 2024

Acumen Pharmaceuticals extends collaboration with Lonza for sabirnetug

Lonza is already involved in the drug substance manufacturing for the Phase II clinical supply of the antibody. Credit: Steve Buissinne from Pixabay.
September 26, 2024

MITEM PHARMA acquires global rights to injectable medicine from Novartis

MITEM PHARMA’s strategy involves identifying therapeutic needs, ensuring the supply and availability of existing medicines. Credit: Sam Moghadam Khamseh on Unsplash.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals July 15, 2024

Merck enhances ophthalmology portfolio with EyeBio acquisition

Pharmaceutical Business Review

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Zuellig Pharma acquires Cialis and Alimta brands from Lilly

Popular

  1. Amgen’s TEPEZZA gets Japan’s MHLW approval for thyroid eye disease treatment
  2. FDA grants fast track designation for Elevation Oncology’s EO-3021
  3. EMA CHMP recommends AbbVie’s mirvetuximab soravtansine for ovarian cancer
  4. Hyphens Pharma introduces new eczema hand balm
  5. Azitra’s ATR-04 receives FDA fast track status for treating skin rash

PRESS RELEASES

Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: EcoVadis Gold with Further Improved Score
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer: Innovative Silicone Oil-Free Syringe Systems for Sensitive Ophthalmic Drugs
Gerresheimer Remains on Track in First Half of 2024
Gerresheimer Remains on Track in First Half of 2024
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy
RWS Joins Meta’s Open Loop Programme to Shape Future of AI Policy

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation